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Abstract:  The aim of this study was to determine the changes of short chain fatty acids (SCFAs) in faeces of 
inflammatory bowel disease (IBD) patients compared to healthy subjects. SCFAs such as pyruvic, lactic, formic, acetic, 
propionic, isobutyric and butyric acids were analyzed by using high performance liquid chromatography (HPLC). This 
study showed that the level of acetic, 162.0 mol/g wet faeces, butyric, 86.9 mol/g wet faeces, and propionic acids, 65.6 
mol/g wet faeces, decreased remarkably in IBD faecal samples when compared with that of healthy individuals, 209.7, 
176.0, and 93.3 mol/g wet faeces respectively. On the contrary, lactic and pyruvic acids showed higher levels in faecal 
samples of IBD than in healthy subjects. In the context of butyric acid level, this study also found that the molar ratio of 
butyric acid was higher than propionic acid in both faecal samples. This might be due to the high intake of starch from 
rice among Malaysian population. It was concluded that the level of SCFAs differ remarkably between faecal samples in 
healthy subjects and that in IBD patients providing evidence that SCFAs more likely play an important role in the 
pathogenesis of IBD.  
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INTRODUCTION  
  Short chain fatty acids (SCFAs), are carboxylic acids 
with 1 to 6 carbon atoms that include different other 
functional groups, such as hydroxyl or dicarboxyl. In human, 
SCFAs arise from bacterial fermentation of carbohydrates, 
proteins, peptides and glycoprotein precursors [1, 2]. SCFAs 
such as acetic, propionic and butyric acids are mainly formed 
during microbial fermentation of carbohydrate in the colon 
[3, 4]. The most important role of SCFAs in colonic 
physiology is their trophic effect on the intestinal epithelium. 
For example, Sakata reported that the presence of SCFAs in 
rat colon stimulates mucosal proliferation [5]. In human, 
SCFAs production from inulin-type fructan can increase the 
metabolic activity, pointing to trophic effects for colonocytes 
[6].  
  Approximately 80-90% of SCFAs, which are produced 
from the breakdown of dietary food, are absorbed in colon 
while the rest are excreted in faeces [7]. SCFAs content in 
faeces could be used as a biomarker for the physiological 
processes in the organisms as well as for the effect of 
nutritional interventions [1]. The level of SCFA content in 
faecal samples have been shown to be related with some 
diseases such as IBD, irritable bowel syndrome (IBS),   
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cardiovascular disease (CVD), diarrhoea [8], and cancer [9]. 
For example, a decreased level of butyric acid in the 
colonocytes has been suggested to contribute to the genesis 
of ulcerative colitis (UC) [10]. It was also reported that 
increased lactic acid may modulate diarrhea in UC [11]. In 
addition, faecal SCFAs, acetic and propionic acids, in 
patients with diarrhea-dominant IBS were found to be of 
lower levels than in healthy individuals [12, 13].  
  Therefore, there has been increasing evidence that the 
majority of SCFAs play an essential role in maintaining the 
health of colonic mucosa. However, butyric, acetic, and 
propionic acids have mainly been emphasized. In particular, 
butyric acid was addressed to be more beneficial for 
promoting colonic health and more effective for stimulating 
the proliferation of intestinal mucosal cells than acetic and 
propionic acids [5]. Butyric acid is also the main energy 
substrate for the colonocytes [14] and it has been suggested 
to play an important role in the prevention and treatment of 
distal UC [10], Crohn’s disease (CD) [15], and cancer [16]. 
In addition, butyric acid appears to induce differentiation of 
tumor cell lines [17]. 
  Several methods were used to analyze the faecal SCFAs 
in rat and human samples. For example, a rapid and reliable 
gas chromatographic (GC) method has been developed and 
validated by Zhao et al. to determine eight SCFAs, in the 
colonic and faecal samples of rats and humans [18]. In 
addition, methods such as vacuum ultrafiltration followed by 
GC, ion chromatography (IC) [19], and IC with solid-phase 54    The Open Biochemistry Journal, 2010, Volume 4  Huda-Faujan et al. 
extraction [20] were used for the determination of SCFAs in 
faecal samples. Furthermore, Scheppach et al. measured 
SCFAs by gas-liquid chromatography using a capillary 
column after purifying the faecal samples by acid vacuum 
transfer and concentration by alkaline freeze-drying [21]. In 
addition to GC, high performance liquid chromatography 
(HPLC) has also been applied to the analysis of faecal 
SCFAs in humans [22, 23] and rats [24]. HPLC is 
convenient for the quantification of SCFAs, and it is less 
time-consuming [25]. Moreover, it does not require any pre-
purification steps when compared to GC [26]. 
  In South East Asia, particularly in Malaysia, IBD has 
been not very common but the incidence of the disease was 
recently increasing. Based on the two types of IBD, UC was 
found to be more common than CD [27]. To date, data on 
IBD cases in South East Asia is still scarce in that very few 
studies, if any, were conducted on the content and the role of 
SCFAs in faeces of healthy and IBD subjects. Therefore, the 
current study was conducted to determine the level of faecal 
SCFAs (pyruvic, lactic, acetic, formic, propionic, butyric and 
isobutyric acids) in IBD patients by using HPLC methods. 
The level of each faecal SCFA was compared to counterpart 
samples from healthy individuals.  
MATERIALS AND METHODOLOGY 
Chemicals and Reagents  
  Formic acid, 98-100%, and acetic acid, 100%, were 
obtained from Merck (Merck, KGaA, Darmstadt, Germany), 
pyruvic acid, 99%, and propionic acid, 99%, were obtained 
from Merck (Merck, DHG, Hohenbrunn, Germany), 
isobutyric acid, 99%, was obtained from Sigma (Sigma-
Aldrich, St. Louis, CA, USA), lactic acid, 100%, and butyric 
acid, 99.5%, were purchased from Fluka (Cheniou, Gmblt, 
Germany).  
The Study Population and Faecal Samples 
  Faecal samples were obtained from 50 healthy subjects 
(male = 18, female = 32) and 8 IBD (male = 6, female = 2) 
subjects from March 2007 to December 2008 in Selangor, 
Malaysia. The age of the studied patients ranged from 34 to 
68 years and the age for the healthy subjects ranged from 22 
to 55 years. Six of IBD patients were at remission phase 
except for 2 UC were at active phase; nevertheless, all of the 
involved patients showed no diarrheal symptoms within 2 
weeks before the time of sampling. The nutritional status of 
the involved patients was within average and patients did not 
change their nutritional habit during sampling. The IBD 
samples were collected from patients who had been 
diagnosed as CD (n=2) and UC (n=6). Diagnosis of IBD was 
confirmed in all cases by colonoscopy and histology. The 
main symptoms of the involved IBD patients within the last 
month were: for UC, loose stools (1 patients), low grade 
fewer (2 patients), mild diarrhea with blood stain (1 patient), 
abdominal pain (1 patients), and abdominal distension (1 
patients), for CD, patients did not have remarkable 
symptoms. Furthermore, IBD patients did not experience any 
extra-intestinal manifestations. It is noteworthy to mention 
that IBD patients and the healthy volunteers did not receive 
antibiotics, probiotics, and prebiotics one month prior to the 
samples collection. Moreover, IBD patients did not receive 
mesalazine 2 weeks before sampling.  
  The faecal samples were collected into clean sterile 
containers. They were immediately taken to the laboratory 
and kept frozen at -20
oC for analysis. Dealing with human 
subjects was carried out within the scope of the ethical 
principles of biomedical research. The ethics committee of 
the University Putra Malaysia and Serdang Hospital and all 
of the involved subjects signed formal written consents.  
Preparation of Samples for Analysis  
  The SCFAs of faecal samples were extracted as 
described by Lee et al. method [28] with slight modification. 
Faecal samples of weight 0.2 g were used and diluted at ratio 
1:4 to 1:8 (w/v) in sterile distilled water. The samples were 
then vortexed for 1 min and the homogenate was centrifuged 
at 10,000g  for 10 min. The SCFA-containing supernatant 
was filtered through cellulose acetate membrane with a pore 
size of 0.2 m (GyroDisc CA; Orange Scientific) and stored 
at -20
oC until HPLC analysis.  
Determination of Organic Acids  
  SCFAs analyses were carried out by using HPLC. 
Briefly, 40 l of faecal samples extraction were injected 
directly into HPLC System (Shimadzu LC-10AD Liquid 
Chromatography) with Shimadzu SPD-6A UV-VIS detector 
(Shimadzu, Kyoto, Japan). SCFA in faecal samples were 
separated using an ionic exchange resin, Aminex HPX-87H 
column, (Aminex HPX-87H, 300 x 7.8 mm, Bio-Rad 
Laboratories, Richmond, USA) at 65
oC. The target 
compounds were detected using a UV detector set at 
wavelength of 210 nm. Filtered 0.01 N H2SO4, through 0.45 
m nylon membrane, was used as a mobile phase at a flow 
rate of 0.6 ml/ min. 
Preparation of Calibration Standard Curve  
  Quantification of SCFAs in faecal samples was carried 
out using external calibration standard curves method. Seven 
calibration standards were prepared at six levels of 
concentration ranging from 0.005M to 0.03M for pyruvic 
acid, 0.01M to 0.06M for formic acid and acetic acid, and 
0.02M to 0.12M for lactic acid, propionic acid, isobutyric 
acid and butyric acid. The reference samples were injected 
repeatedly for nine times to measure the retention time. The 
calibration curves were constructed by plotting the relative 
peak area versus the molarity of solution. Faecal SCFA 
concentrations were expressed as mean mol per gram wet 
weight faeces using the following equation as described by 
Hoshi et al. [29] with modification. 
Faecal SCFA (mol/g) = [organic acid in faecal contents 
(mmol/ml) X Vd (ml) X 1000]/ Wet weight faeces (g) 
Whereas: Vd = Total Volume of Dilution  
Statistical Analysis  
  Data analysis was conducted using MINITAB version 14 
(Minitab Inc., PA, USA). The normality of data was checked 
using Anderson-Darling test before statistical analysis was 
done. Differences between means of SCFA concentration 
between healthy and IBD groups were analyzed by using 
unpaired Student’s t-test. The means were considered 
statistically significant at P<0.05. Data was expressed in 
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RESULT 
Validation of Retention Time for Analytical Methods 
  The reference standard in different concentrations was 
analyzed on three different days to show the retention times. 
Since external standard was used for calibration, the method 
requires precise analytical technique and requires that the 
detector sensitivity must be constant from day to day if the 
calibration curve is to remain valid [30]. Samples were 
injected nine times in different concentrations and the 
average of retention time (Rt) was used. From the analysis, 
the Rt for pyruvic, lactic, formic, acetic, propionic, isobutyric 
and butyric acids was 9.28, 12.07, 13.38, 14.60, 17.28, 
19.49, and 21.82 min respectively.  
Short Chain Fatty Acids in Faecal Samples 
  The mean concentrations of SCFA in faecal samples of 
healthy and IBD subjects are shown in Table 1. From the 
table, results revealed that the mean concentrations of butyric 
and propionic acids, 86.9 and 65.6 mol/g wet faeces, 
respectively in IBD faecal samples were lower than in 
healthy subjects, 176.0 and 93.3 mol/g wet faeces 
respectively (P<0.05). Acetic acid was also lower in faecal 
samples of IBD patients than of healthy subjects but the 
difference was not so significant (p=0.16).  
  The faecal concentration of formic acid, isobutyric, lactic 
and pyruvic acids were also determined and compared 
between healthy and IBD groups. Formic acid was only 
detected in five healthy subjects and isobutyric acid was only 
detected in two samples of healthy group while no detection 
of formic and isobutyric acids was found in the faecal 
samples of IBD patients. In contrary, the faecal 
concentration of lactic and pyruvic acids was lower in 
healthy subjects, 24.5 mol/g and 0.5 mol/g respectively, 
than in IBD patients, 73.5 mol/g and 2.1 mol/g 
respectively, but this difference was not significant (P 
>0.05). 
Molar Ratio of Main SCFA in Faecal Samples 
  There has been no report about the molar ratio of main 
SCFAs in faecal samples in Malaysian subjects. Therefore, 
the molar ratio of acetic, propionic and butyric acids were 
calculated. From the current study, the molar ratio of acetic: 
propionic: butyric acids in faecal samples of healthy subjects 
were 45:20:38 and in faecal samples of IBD were 49:20:27. 
This finding showed that the molar ratio of butyric acid and 
propionic was 1.5 and 1.35 in healthy and IBD subjects, 
respectively. 
DISCUSSION 
  In this study, it was shown that butyric and propionic 
acids were decreased significantly in IBD subjects. This 
finding was similar to that reported by Takaishi et al. [22] 
who revealed that the concentrations of butyric and 
propionic acids were significantly decreased in IBD patients 
than in healthy controls. In addition, Vernia et al. [11] and 
Hallert et al. [31] reported similar decreasing trend of butyric 
acid in UC patients. However, another study reported that 
although there was a decreased butyric acid level in active 
UC, the difference was not significant between healthy and 
patients groups [32]. The decreasing level of butyric acid 
could be due to the assumption that the distribution of 
intestinal microbiota changes in IBD patients [22]. 
Furthermore, it was reported that the faecal proportion of 
butyric acid in patients with UC increased after consuming 
oat bran [3]. It was stated that the increase in butyric acid 
level may have an advantage to play a role in the prevention 
of UC [10]. Moreover, it was suggested that when the 
butyric acid is low in UC patients, the risk of colon cancer 
increases [33]. On the other hand, the increasing propionic 
acid was shown to be associated with decreasing serum 
cholesterol in blood [34]. 
  Comparing acetic acid concentration between healthy 
and IBD faecal samples, Takaishi et al. also reported that the 
acetic acid in IBD faeces was not significantly lower than in 
healthy control and they found that the concentration of 
acetic acid in CD was lower than in UC [22]. This report was 
consistent with that reported by Stein et al. [35] that the 
amount of acetic acid in faecal samples of CD was lower 
(135.9  mol/ g dry faeces, n=8) than in healthy subjects 
(161.9 mol/ g dry faeces, n=10). Furthermore, Nilsson et al. 
reported that the mean level of acetic acid in healthy subjects 
(n=20) before giving oat bran diet was 54.2 mol/g wet 
faeces ranging from 19.5 mol/g to 126.2 mol/g of faeces 
[36]. They showed that, after 8 weeks of giving oat bran, the 
mean level of acetic acid increased 77.2 mol/g wet faeces 
Table 1.   SCFA in Faecal Samples of IBD Patients and Healthy Subjects 
  Healthy Subjects (n=50)  Range  % PC*  IBD Subjects (n=8)  Range %  PC  P-values 
Acetic Acid  209.7 ± 14.0  21.5 – 400.5  (100)  162.0 ± 28.0  64.2 – 308.9  (100)  0.160 
Butyric Acid  176.0 ± 16.0
*  45.2 – 503.3  (100)  86.9 ± 21.0
*  32.7 – 204.2  (100)  0.004 
Propionic Acid  93.3 ± 5.3
*  33.8 – 185.1  (100)  65.6 ± 5.3
*  45.1 – 91.7  (100)  0.001 
Lactic Acid  24.5 ± 4.8  0 – 120.6  (48)  73.5 ± 37.0  0 – 254.4  (62.5)  0.237 
Formic Acid  21.5 ± 9.7  0 – 364.2  (10)  No detection       
Pyruvic Acid  0.5 ± 0.3  0 – 16.4  (8)  2.1 ± 1.3   0 – 10.1  (37.5)  0.261 
Isobutyric Acid  17.9 ± 13.2  0 – 591.3  (4)  No detection       
*PC = Positive cases. 
Results are expressed in mol/g wet faeces (mean ± SEM). 
Value marked with asterisk are significantly different between two groups (P<0.05). 56    The Open Biochemistry Journal, 2010, Volume 4  Huda-Faujan et al. 
ranging from 22.9 to 125.6 mol/g of faeces (P<0.001). And 
acetic acid absorption in the colon has been shown to 
increase cholesterol synthesis. However, addition of 
propionate to acetate resulted in no significant rise in 
cholesterol [37]. This finding was supported by Wong et al. 
[38] that the acetate: propionate ratio may reduce serum 
lipids and possibly decrease cardiovascular disease risk. 
  With respect to lactic acid, the current study yielded 
similar results to a previous report stating that higher lactic 
acid concentration was found in both of faecal UC and CD 
samples than in healthy subjects [8]. High concentration of 
lactic acid was associated with higher risk of diarrhoea and 
mucosal inflammation [2]. Previously, a study reported that 
faecal lactate rises in patients with acidorrhea [39]. The 
importance of low lactic acid concentration in faecal samples 
of healthy subjects is still unknown. However, lactic acid can 
be further metabolized by propionibacteria to propionic acid 
and acetic acid [40]. Butyric acid can be also produced from 
lactic acid through the acetyl-CoA pathway [41].  
  In this study, faecal formic acid was only detected in five 
healthy subjects. Quantification of formic acid in faecal 
samples was always unsatisfactory and frequently at very 
low or undetectable level [42]. This might be attributed to 
the fact that formic acid has been believed to be formed by 
microorganisms in the colon only at the initial phase of 
dietary fermentation [43]. Furthermore, formic acid is an 
intermediate product, not an end-product, of bacterial 
fermentation and is converted readily to CO2 and water [44]. 
Furthermore, formic acid was probably metabolised by 
bacterial enzymes during incubation at 50°C. In addition, it 
is extremely volatile and losses cannot be avoided during 
preparation of sample. For these reasons formic acid in 
faeces is rarely detected [42]. 
 Takaishi  et al. [22] and Vernia et al. [8] showed that 
pyruvic and succinic acids in faecal IBD were higher than in 
healthy subjects and they found that the concentration of 
pyruvic acid in patients with UC was significantly higher 
than in patients with CD. Their findings are similar to that of 
current study that pyruvic acid was higher in faecal IBD than 
in healthy group. However, this increase was not 
significantly different.  
  Other SCFAs such as iso-butyric, n-valeric, iso-valeric 
and n-caproic acids were presented in minor amounts in the 
human colon. Similarly, it was reported that all these SCFAs 
were too low to be detected [45]. The branched chain fatty 
acids (BCFA), iso-butyric and iso-valeric acids are primarily 
produced from catabolism of protein particularly from 
branched amino acids fermentation [46]. An increase of 
BCFA tends to be observed only when carbohydrate is 
limited [47]. 
  Approximately, these SCFAs account for 90 to 95 % of 
total fatty acids. Of the SCFAs, the major products are 
acetic, propionic, and butyric acids which are commonly 
found in proportions approximately 60:20:20 (acetic: 
propionic: butyric) [1, 38]. However, these ratios are very 
rare to achieve in practice. The patterns of the molar ratio of 
SCFA awere ttributed to the bacterial species present. In 
addition, it was also influenced by the composition of diet 
and type of indigestible carbohydrates [3]. Moreover, the 
molar ratio of butyric and propionic acids was 1.5 and 1.35 
in healthy and IBD subjects which might be due to the high 
intake of starch from rice among the Malaysian people. 
  The possible anti-inflammatory mechanism of SCFAs, 
namely propionic, butyric, and acetic acids, are still not 
clarified adequately. However, a recent study showed that 
propionic and butyric acids were equipotent, whereas acetic 
acid was less effective, at suppressing NF-kappaB reporter 
activity, inflammation-related gene expression and cytokine 
release  in vitro. Therefore, these findings suggested that 
propionic and acetic acids, in addition to butyric acid, could 
be useful in the treatment of inflammatory disorders, 
including IBD [48]. Moreover, it was shown that butyric 
acid suppresses nuclear factor-kappaB activation via 
GPR109A receptors in normal and cancer colon cell lines as 
well as in normal mouse colon. This study showed that 
GPR109A mediates the tumor-suppressive effects of the 
bacterial fermentation product, butyric acid in colon [49]. In 
addition, it was confirmed that SCFA, adenine nucleotides, 
and phospholipids can modulate intestinal epithelial repair 
mechanisms. Given that repeated damage and injury of the 
intestinal surface are key features of various intestinal 
disorders including inflammatory bowel diseases, SCFA are 
essential for the constant repair of the colon epithelium [50]. 
CONCLUSION 
  From this study, it was concluded that the level of SCFAs 
might play an important role in the pathophysiology and/or 
progression of IBD. The current study showed that the level 
of SCFAs differs remarkably between the faecal samples of 
healthy subjects and these of IBD patients. As compared to 
the healthy subjects, acetic, butyric and propionic acids 
decreased dramatically in faecal samples of IBD as well as 
formic and isobutyric acids were not detectable in faecal 
samples of IBD while the level of acetic and pyruvic acids 
increased in faeces of IBD patients. In this study, the molar 
ratio of butyric acid also showed higher proportion than 
propionic acid in faecal samples and might be due to the 
high intake of starch from rice among Malaysian. However, 
future studies need larger sample size to determine more 
precisely the distribution of SCFAs among IBD patients in 
the region of South East Asia. The relationship between rice 
consumption and the reduction of IBD incidence also need to 
be determined since the incidence of IBD in the region of 
South East Asia is still not very common. 
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